Clinical trial
Safety and Immunological Response Rate Study of THERATOPE® Vaccine in Metastatic…
NCT00046371 · Oncothyreon Canada Inc., Industry · Completed
Key facts
| NCT number | NCT00046371 |
|---|---|
| Title | Safety and Immunological Response Rate Study of THERATOPE® Vaccine in Metastatic Breast Cancer Patients |
| Official title | Open-Label, Phase II Trial of Immunological Response Rate, Safety, and Tolerability of THERATOPE® Vaccine in Subjects With Metastatic Breast Cancer Undergoing Treatment With Aromatase Inhibitors or Faslodex® |
| Lead sponsor | Oncothyreon Canada Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | THERATOPE® vaccine |
| Start date | Aug 1, 2002 |
| Completion | Aug 1, 2005 |
| First posted | Oct 10, 2002 |
| Last update posted | Jan 23, 2008 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: